

# Chemotherapy Induced Peripheral Neuropathy Treatment Market - Global Outlook and Forecast 2021-2027

<https://marketpublishers.com/r/CBD939F4BCAEEN.html>

Date: March 2021

Pages: 93

Price: US\$ 3,250.00 (Single User License)

ID: CBD939F4BCAEEN

## Abstracts

This report contains market size and forecasts of Chemotherapy Induced Peripheral Neuropathy Treatment in global, including the following market information:

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue, 2016-2021, 2022-2027, (\$ millions)

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Sales, 2016-2021, 2022-2027, (K Units)

Global top five Chemotherapy Induced Peripheral Neuropathy Treatment companies in 2020 (%)

The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at 1618.1 million in 2020 and is projected to reach US\$ 2052.5 million by 2027, at a CAGR of 6.1% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Type,

2016-2021, 2022-2027 (\$ Millions) & (K Units)

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, By Type, 2020 (%)

Calcium Channel  $\gamma$ 2-delta Ligands

Antidepressants

Opioids

Others

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Application, 2016-2021, 2022-2027 (\$ Millions) & (K Units)

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, By Application, 2020 (%)

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Region and Country, 2016-2021, 2022-2027 (\$ Millions) & (K Units)

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, By Region and Country, 2020 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues in global market, 2016-2021 (Estimated), (\$ millions)

Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues share in global market, 2020 (%)

Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales in global market, 2016-2021 (Estimated), (K Units)

Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales share in global market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT OVERALL MARKET SIZE**

- 2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size: 2021 VS 2027
- 2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Prospects & Forecasts: 2016-2027
- 2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Consumption): 2016-2027

### **3 COMPANY LANDSCAPE**

- 3.1 Top Chemotherapy Induced Peripheral Neuropathy Treatment Players in Global Market
- 3.2 Top Global Chemotherapy Induced Peripheral Neuropathy Treatment Companies Ranked by Revenue
- 3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Companies
- 3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Companies
- 3.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Manufacturer (2016-2021)
- 3.6 Top 3 and Top 5 Chemotherapy Induced Peripheral Neuropathy Treatment

Companies in Global Market, by Revenue in 2020

3.7 Global Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type

3.8 Tier 1, Tier 2 and Tier 3 Chemotherapy Induced Peripheral Neuropathy Treatment Players in Global Market

3.8.1 List of Global Tier 1 Chemotherapy Induced Peripheral Neuropathy Treatment Companies

3.8.2 List of Global Tier 2 and Tier 3 Chemotherapy Induced Peripheral Neuropathy Treatment Companies

## **4 SIGHTS BY PRODUCT**

4.1 Overview

4.1.1 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Markets, 2021 & 2027

4.1.2 Calcium Channel  $\alpha$ -2-delta Ligands

4.1.3 Antidepressants

4.1.4 Opioids

4.1.5 Others

4.2 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue & Forecasts

4.2.1 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2021

4.2.2 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2022-2027

4.2.3 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

4.3 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales & Forecasts

4.3.1 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2021

4.3.2 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2022-2027

4.3.3 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

4.4 By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (Manufacturers Selling Prices), 2016-2027

## **5 SIGHTS BY APPLICATION**

## 5.1 Overview

5.1.1 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2021 & 2027

5.1.2 Platinum Agents

5.1.3 Taxanes

5.1.4 Vinca Alkaloids

5.1.5 Others

5.2 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue & Forecasts

5.2.1 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2021

5.2.2 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2022-2027

5.2.3 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

5.3 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales & Forecasts

5.3.1 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2021

5.3.2 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2022-2027

5.3.3 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

5.4 By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (Manufacturers Selling Prices), 2016-2027

## 6 SIGHTS BY REGION

6.1 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2021 & 2027

6.2 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue & Forecasts

6.2.1 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2021

6.2.2 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2022-2027

6.2.3 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027



## 6.3 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales & Forecasts

6.3.1 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2021

6.3.2 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2022-2027

6.3.3 By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

## 6.4 North America

6.4.1 By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2027

6.4.2 By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2027

6.4.3 US Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.4.4 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.4.5 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

## 6.5 Europe

6.5.1 By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2027

6.5.2 By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2027

6.5.3 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.5.4 France Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.5.5 U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.5.6 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.5.7 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.5.8 Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.5.9 Benelux Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

## 6.6 Asia

6.6.1 By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2027

6.6.2 By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2027

6.6.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.6.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.6.5 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.6.6 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.6.7 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.7 South America

6.7.1 By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2027

6.7.2 By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2027

6.7.3 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.7.4 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2027

6.8.2 By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, 2016-2027

6.8.3 Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.8.4 Israel Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.8.5 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

6.8.6 UAE Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2016-2027

## **7 MANUFACTURERS & BRANDS PROFILES**

## 7.1 Aptinyx Inc

7.1.1 Aptinyx Inc Corporate Summary

7.1.2 Aptinyx Inc Business Overview

7.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

7.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

7.1.5 Aptinyx Inc Key News

## 7.2 Asahi Kasei Pharma Corp

7.2.1 Asahi Kasei Pharma Corp Corporate Summary

7.2.2 Asahi Kasei Pharma Corp Business Overview

7.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

7.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

7.2.5 Asahi Kasei Pharma Corp Key News

## 7.3 Regency Pharmaceuticals

7.3.1 Regency Pharmaceuticals Corporate Summary

7.3.2 Regency Pharmaceuticals Business Overview

7.3.3 Regency Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

7.3.4 Regency Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

7.3.5 Regency Pharmaceuticals Key News

## 7.4 MAKScientific LLC

7.4.1 MAKScientific LLC Corporate Summary

7.4.2 MAKScientific LLC Business Overview

7.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

7.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

7.4.5 MAKScientific LLC Key News

## 7.5 Metys Pharmaceuticals AG

7.5.1 Metys Pharmaceuticals AG Corporate Summary

7.5.2 Metys Pharmaceuticals AG Business Overview

7.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

7.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

- 7.5.5 Metys Pharmaceuticals AG Key News
- 7.6 Nemus Bioscience Inc
  - 7.6.1 Nemus Bioscience Inc Corporate Summary
  - 7.6.2 Nemus Bioscience Inc Business Overview
  - 7.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
  - 7.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)
  - 7.6.5 Nemus Bioscience Inc Key News
- 7.7 PledPharma
  - 7.7.1 PledPharma Corporate Summary
  - 7.7.2 PledPharma Business Overview
  - 7.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
  - 7.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)
  - 7.7.5 PledPharma Key News
- 7.8 Sova Pharmaceuticals Inc
  - 7.8.1 Sova Pharmaceuticals Inc Corporate Summary
  - 7.8.2 Sova Pharmaceuticals Inc Business Overview
  - 7.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
  - 7.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)
  - 7.8.5 Sova Pharmaceuticals Inc Key News
- 7.9 DermaXon LLC
  - 7.9.1 DermaXon LLC Corporate Summary
  - 7.9.2 DermaXon LLC Business Overview
  - 7.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
  - 7.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)
  - 7.9.5 DermaXon LLC Key News
- 7.10 Kineta Inc
  - 7.10.1 Kineta Inc Corporate Summary
  - 7.10.2 Kineta Inc Business Overview
  - 7.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings
  - 7.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and

## Revenue in Global (2016-2021)

### 7.10.5 Kineta Inc Key News

## 7.11 Krenitsky Pharmaceuticals Inc

### 7.11.1 Krenitsky Pharmaceuticals Inc Corporate Summary

### 7.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview

### 7.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

### 7.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

### 7.11.5 Krenitsky Pharmaceuticals Inc Key News

## 7.12 PeriphaGen

### 7.12.1 PeriphaGen Corporate Summary

### 7.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview

### 7.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

### 7.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

### 7.12.5 PeriphaGen Key News

## 7.13 Apexian Pharma

### 7.13.1 Apexian Pharma Corporate Summary

### 7.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview

### 7.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

### 7.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

### 7.13.5 Apexian Pharma Key News

## 7.14 WinSanTor

### 7.14.1 WinSanTor Corporate Summary

### 7.14.2 WinSanTor Business Overview

### 7.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Major Product Offerings

### 7.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue in Global (2016-2021)

### 7.14.5 WinSanTor Key News

## **8 GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY**

## **TREATMENT PRODUCTION CAPACITY, ANALYSIS**

8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity, 2016-2027

8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity of Key Manufacturers in Global Market

8.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region

## **9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS**

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

## **10 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT SUPPLY CHAIN ANALYSIS**

10.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Value Chain

10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Upstream Market

10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors and Sales Agents in Global

## **11 CONCLUSION**

## **12 APPENDIX**

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Key Players of Chemotherapy Induced Peripheral Neuropathy Treatment in Global Market

Table 2. Top Chemotherapy Induced Peripheral Neuropathy Treatment Players in Global Market, Ranking by Revenue (2019)

Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Companies, (US\$, Mn), 2016-2021

Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Companies, 2016-2021

Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Companies, (K Units), 2016-2021

Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Companies, 2016-2021

Table 7. Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Price (2016-2021) & (US\$/Unit)

Table 8. Global Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type

Table 9. List of Global Tier 1 Chemotherapy Induced Peripheral Neuropathy Treatment Companies, Revenue (US\$, Mn) in 2020 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Chemotherapy Induced Peripheral Neuropathy Treatment Companies, Revenue (US\$, Mn) in 2020 and Market Share

Table 11. By Type – Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2021 VS 2027

Table 12. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US\$, Mn), 2016-2021

Table 13. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US\$, Mn), 2022-2027

Table 14. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2016-2021

Table 15. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2022-2027

Table 16. By Application – Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2021 VS 2027

Table 17. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US\$, Mn), 2016-2021

Table 18. By Application - Global Chemotherapy Induced Peripheral Neuropathy

Treatment Revenue (US\$, Mn), 2022-2027

Table 19. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2016-2021

Table 20. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2022-2027

Table 21. By Region – Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2021 VS 2027

Table 22. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US\$, Mn), 2016-2021

Table 23. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US\$, Mn), 2022-2027

Table 24. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2016-2021

Table 25. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2022-2027

Table 26. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2021

Table 27. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2022-2027

Table 28. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2016-2021

Table 29. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2022-2027

Table 30. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2021

Table 31. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2022-2027

Table 32. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2016-2021

Table 33. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2022-2027

Table 34. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2021

Table 35. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2022-2027

Table 36. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2016-2021

Table 37. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2022-2027



- Table 38. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2021
- Table 39. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2022-2027
- Table 40. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2016-2021
- Table 41. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2022-2027
- Table 42. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2021
- Table 43. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2022-2027
- Table 44. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2016-2021
- Table 45. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (K Units), 2022-2027
- Table 46. Aptinyx Inc Corporate Summary
- Table 47. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
- Table 48. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)
- Table 49. Asahi Kasei Pharma Corp Corporate Summary
- Table 50. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
- Table 51. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)
- Table 52. Regenacy Pharmaceuticals Corporate Summary
- Table 53. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
- Table 54. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)
- Table 55. MAKScientific LLC Corporate Summary
- Table 56. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
- Table 57. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)
- Table 58. Metys Pharmaceuticals AG Corporate Summary

Table 59. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 60. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 61. Nemus Bioscience Inc Corporate Summary

Table 62. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 63. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 64. PledPharma Corporate Summary

Table 65. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 66. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 67. Sova Pharmaceuticals Inc Corporate Summary

Table 68. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 69. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 70. DermaXon LLC Corporate Summary

Table 71. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 72. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 73. Kineta Inc Corporate Summary

Table 74. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 75. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 76. Krenitsky Pharmaceuticals Inc Corporate Summary

Table 77. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 78. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 79. PeriphaGen Corporate Summary

Table 80. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 81. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 82. Apexian Pharma Corporate Summary

Table 83. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 84. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 85. WinSanTor Corporate Summary

Table 86. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings

Table 87. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2016-2021)

Table 88. Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity (K Units) of Key Manufacturers in Global Market, 2019-2021 (K Units)

Table 89. Global Chemotherapy Induced Peripheral Neuropathy Treatment Capacity Market Share of Key Manufacturers, 2019-2021

Table 90. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region, 2016-2021 (K Units)

Table 91. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Region, 2022-2027 (K Units)

Table 92. Chemotherapy Induced Peripheral Neuropathy Treatment Market Opportunities & Trends in Global Market

Table 93. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers in Global Market

Table 94. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints in Global Market

Table 95. Chemotherapy Induced Peripheral Neuropathy Treatment Raw Materials

Table 96. Chemotherapy Induced Peripheral Neuropathy Treatment Raw Materials Suppliers in Global Market

Table 97. Typical Chemotherapy Induced Peripheral Neuropathy Treatment Downstream

Table 98. Chemotherapy Induced Peripheral Neuropathy Treatment Downstream Clients in Global Market

Table 99. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors and Sales Agents in Global Market

## List Of Figures

### LIST OF FIGURES

Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type

Figure 2. Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application

Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview: 2020

Figure 4. Key Caveats

Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size: 2021 VS 2027 (US\$, Mn)

Figure 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2016-2027 (US\$, Mn)

Figure 7. Chemotherapy Induced Peripheral Neuropathy Treatment Sales in Global Market: 2016-2027 (K Units)

Figure 8. The Top 3 and 5 Players Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2020

Figure 9. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 10. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 11. By Type - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US\$/Unit), 2016-2027

Figure 12. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 13. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 14. By Application - Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US\$/Unit), 2016-2027

Figure 15. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 16. By Region - Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 17. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 18. By Country - North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 19. US Chemotherapy Induced Peripheral Neuropathy Treatment Revenue,

(US\$, Mn), 2016-2027

Figure 20. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 21. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 22. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 23. By Country - Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 24. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 25. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 26. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 27. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 28. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 29. Nordic Countries Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 30. Benelux Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 31. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 32. By Region - Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 33. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 34. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 35. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 36. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 37. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 38. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 39. By Country - South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 40. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 41. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 42. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share, 2016-2027

Figure 43. By Country - Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share, 2016-2027

Figure 44. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 45. Israel Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 46. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 47. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US\$, Mn), 2016-2027

Figure 48. Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Capacity (K Units), 2016-2027

Figure 49. The Percentage of Production Chemotherapy Induced Peripheral Neuropathy Treatment by Region, 2020 VS 2027

Figure 50. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Value Chain

Figure 51. Marketing Channels

## I would like to order

Product name: Chemotherapy Induced Peripheral Neuropathy Treatment Market - Global Outlook and Forecast 2021-2027

Product link: <https://marketpublishers.com/r/CBD939F4BCAEEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CBD939F4BCAEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

